YOKNEAM, Israel, May 9, 2019 /PRNewswire/ -- Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, is proud to announce that its patented MOSES Urology Laser Technology has garnered Lumenis finalist status in the 2019 Medical Design Excellence Awards (MDEA). MOSES, already adopted by hundreds of healthcare facilities worldwide, has demonstrated a variety of clinical advantages and benefits in both Holmium Laser Lithotripsy and Benign Prostatic Hyperplasia (BPH) treatments, including faster procedures, optimized energy delivery, and greater ablation efficiency.
The MDEA program celebrates the "accomplishments of the medical device manufacturers, their suppliers, and the many people behind the scenes — engineers, scientists, designers, and clinicians — who are responsible for the cutting-edge products that are saving lives, improving patient healthcare, and transforming medtech, one innovation at a time." The 2019 MDEA Juror Panel, comprised of practicing doctors, nurses, technicians, industrial designers, engineers, manufacturers, and human factors experts, selected 46 exceptional finalists in nine medical technology product categories. MOSES was chosen as one of the six finalists in the ER and OR Tools, Equipment, and Supplies category. Products and technologies were judged based on patient benefits, business benefits, overall benefit to the healthcare system, design and engineering innovation and function, and user-related innovation.
"We are honored to receive recognition by MDEA for the MOSES Technology, which is redefining the standard of care in lithotripsy and BPH treatment," commented Tzipi Ozer-Armon, CEO of Lumenis. "Innovative technologies like MOSES are the result of Lumenis' heritage of innovation and longevity in the world of medical devices and medical laser technology. MOSES is the manifestation of our continuous collaboration with key opinion leaders as well as with leading teaching and research institutions, who were deeply involved in the development of this groundbreaking technology. On behalf of the entire Lumenis team, we are grateful for finalist status and extend congratulations to all other finalists."
For the last 30 years, holmium lasers and fibers have been clinically proven as the gold-standard modality for the treatment of urinary stones and BPH. Released by Lumenis two years ago, MOSES is a revolutionary, patent-protected technology. MOSES utilizes a proprietary combination of holmium lasers and fibers that optimize holmium energy transmission using a unique pulse modulation. Significant clinical evidence highlighting the benefits of MOSES in lithotripsy have demonstrated a 20% reduction in procedure time, 25% improvement in fragmentation efficiency and 60% reduction in stone retropulsion.
The advantages of MOSES for lithotripsy and BPH procedures are continuously researched and demonstrated by leading academic institutions worldwide. In BPH procedures, clinical evaluations are ongoing and focused on studying advantages in enucleation of the prostate, including smoother incision, better hemostasis and shorter procedure time. In lithotripsy, the advantages of MOSES are studied across a number of procedures and techniques including Mini PCNL, Ultra Mini PCNL, Flexible Ureteroscopy and RIRS.
The MDEA program is presented by UBM, the global advanced manufacturing and MedTech authority, and by Medical Device and Diagnostic Industry (MD+DI), the industry's central source for late breaking news, information, and business intelligence. For more information about the Medical Design Excellence Awards—including additional details about the manufacturers and suppliers that created the 2019 MDEA-winning products—visit the MDEA website at www.MDEAwards.com or e-mail: email@example.com.
Lumenis is the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications in the area of minimally invasive clinical solutions. Regarded as a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods.
SOURCE Lumenis Ltd.